Molecular Medicine

, Volume 20, Issue 1, pp 164–178 | Cite as

Secreted Frizzled Related Protein 1 Modulates Taxane Resistance of Human Lung Adenocarcinoma

  • Jin Ren
  • Rui Wang
  • Haizhu Song
  • Guichun Huang
  • Longbang Chen
Research Article


Taxanes, such as docetaxel and taxol, have been used as firstline chemotherapies in advanced lung adenocarcinoma (LAD), but limited responses to chemotherapy remain a major impediment in the clinic. Treatment with 5-azacytidine increases the sensitivity of SPC-A1/DTX cell line to taxanes. The results of DNA methylation microarray and cDNA array analysis indicate that DNA methylation contributes to the downregulation of secreted frizzled related protein 1 (SFRP1) in SPC-A1/DTX cells. Overexpression of SFRP1 reverses the chemoresistance of taxane-resistant LAD cell lines and enhances the invivosensitivity of taxane-resistant LAD cells to taxanes. Meanwhile, short hairpin RNA (shRNA)-mediated SFRP1 knockdown decreases the sensitivity of parental LAD cell lines to taxanes. Furthermore, FH535, a reversible Wnt signaling inhibitor, enhances the sensitivity of taxane-resistant LAD cells to taxanes. The level of SFRP1 in tumors of nonresponding patients is significantly lower than that in tumors of responders. Taken together, our results provide the direct evidence that SFRP1 is a clinically important determinant of taxanes resistance in human LAD cells, suggesting that SFRP1 might be a novel therapeutic target for the treatment of taxane-resistant LAD patients.



This work was supported by the National Natural Science Foundation of China (Grant No. 81172106 and 81172335).

Supplementary material

10020_2014_2001164_MOESM1_ESM.pdf (1.4 mb)
Supplementary material, approximately 1.41 MB.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics, 2002. CA. Cancer J. Clin. 55:74–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, et al. (2008) Cancer statistics, 2008. CA. Cancer J. Clin. 58:71–96.CrossRefGoogle Scholar
  3. 3.
    Yvon AM, Wadsworth P, Jordan MA. (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell. 10:947–59.Google Scholar
  4. 4.
    Wang TH, Wang HS, Soong YK. (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 88:2619–28.CrossRefGoogle Scholar
  5. 5.
    Ramachandran K, et al. (2009) Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 69:1527–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Jin B, Robertson KD. (2013) DNA methyltransferases, DNA damage repair, and cancer. Adv. Exp. Med. Biol. 754:3–29.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gordian E, Ramachandran K, Singal R. (2009) Methylation mediated silencing of TMS1 in breast cancer and its potential contribution to docetaxel cytotoxicity. Anticancer Res. 29:3207–10.PubMedGoogle Scholar
  8. 8.
    Dennis S, Aikawa M, Szeto W, d’Amore PA, Papkoff J. (1999) A secreted frizzled related protein, FrzA, selectively associates with Wnt-1 protein and regulates wnt-1 signaling. J. Cell Sci. 112(Pt 21):3815–20.PubMedGoogle Scholar
  9. 9.
    Uren A, et al. (2000) Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J Biol. Chem. 275:4374–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Caldwell GM, et al. (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 64:883–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Fukui T, et al. (2005) Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene. 24:6323–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Veeck J, et al. (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 25:3479–88.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang YW, et al. (2010) Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma. 57:228–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Feng B, Wang R, Song HZ, Chen LB. (2012) MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer. 118:3365–76.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang R, Zhang YW, Chen LB. (2010) Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer. 69:239–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Dumontet C, Jordan MA, Lee FF. (2009) Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol. Cancer Ther. 8:17–25.CrossRefPubMedGoogle Scholar
  17. 17.
    Baird RD, Kaye SB. (2003) Drug resistance reversal—are we getting closer? Eur. J. Cancer. 39:2450–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang R, Huang J, Feng B, De W, Chen L. (2012) Identification of ING4 (inhibitor of growth 4) as a modulator of docetaxel sensitivity in human lung adenocarcinoma. Mol. Med. 18:874–86.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Kastl L, Brown I, Schofield AC. (2010) Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells. Int. J. Oncol. 36:1235–41.PubMedGoogle Scholar
  20. 20.
    Boren T, et al. (2009) MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol. Oncol. 113:249–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Rui W, Bing F, Hai-Zhu S, Wei D, Long-Bang C. (2010) Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J. Cell. Mol. Med. 14:206–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Feng B, Wang R, Chen LB. (2012) MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 317:184–91.CrossRefPubMedGoogle Scholar
  23. 23.
    Cortes-Sempere M, et al. (2013) IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene. 32:1274–83.CrossRefPubMedGoogle Scholar
  24. 24.
    Mattern J, Eichhorn U, Kaina B, Volm M. (1998) O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int. J. Cancer. 77:919–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Gil EY, et al. (2012) Promoter methylation of RASSF1A modulates the effect of the micro-tubule-targeting agent docetaxel in breast cancer. Int. J. Oncol. 41:611–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Wang N, et al. (2012) TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J. Exp. Clin. Cancer Res. 31: 6.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kawano Y, Kypta R. (2003) Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116:2627–34.CrossRefPubMedGoogle Scholar
  28. 28.
    Saran U, Arfuso F, Zeps N, Dharmarajan A. (2012) Secreted Frizzled-Related protein 4 expression is positively associated with responsiveness to Cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers. BMC Cell. Biol. 13: 25.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Su HY, et al. (2010) Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int. J. Cancer. 127:555–67.CrossRefPubMedGoogle Scholar
  30. 30.
    Takada T, et al. (2004) Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci. 95:741–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Gauger KJ, Chenausky KL, Murray ME, Schneider SS. (2011) SFRP1 reduction results in an increased sensitivity to TGF-beta signaling. BMC Cancer. 11: 59.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Jiang GX, et al. (2010) Reconstitution of secreted frizzled-related protein 1 suppresses tumor growth and lung metastasis in an orthotopic model of hepatocellular carcinoma. Dig. Dis. Sci. 55:2838–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Hu J, et al. (2009) Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res. 69:6951–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Pode-Shakked N, et al. (2011) Resistance or sensitivity of Wilms’ tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene. 30:1664–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Cooper SJ, et al. (2012) Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Mol. Cancer Ther. 11:2105–15.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Alfieri CM, Cheek J, Chakraborty S, Yutzey KE. (2010) Wnt signaling in heart valve development and osteogenic gene induction. Dev. Biol. 338:127–35.CrossRefPubMedGoogle Scholar
  37. 37.
    Hu M, et al. (2007) Wnt/beta-catenin signaling in murine hepatic transit amplifying progenitor cells. Gastroenterology. 133:1579–91.CrossRefPubMedGoogle Scholar
  38. 38.
    Inagawa S, et al. (2002) Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin. Cancer Res. 8:450–6.PubMedGoogle Scholar
  39. 39.
    Cagatay T, Ozturk M. (2002) P53 mutation as a source of aberrant beta-catenin accumulation in cancer cells. Oncogene. 21:7971–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Noda T, et al. (2009) Activation of Wnt/betacatenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br. J. Cancer. 100:1647–58.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Bjorklund CC, et al. (2011) Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J. Biol. Chem. 286:11009–20.CrossRefPubMedGoogle Scholar
  42. 42.
    Liao DJ, Thakur A, Wu J, Biliran H, Sarkar FH. (2007) Perspectives on c-Myc, cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit. Rev. Oncog. 13:93–158.CrossRefPubMedGoogle Scholar
  43. 43.
    Kajiyama H, et al. (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 31:277–83.PubMedGoogle Scholar
  44. 44.
    Jeays-Ward K, et al. (2003) Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development. 130:3663–70.CrossRefPubMedGoogle Scholar
  45. 45.
    Yook JI, et al. (2006) A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat. Cell. Biol. 8:1398–406.CrossRefPubMedGoogle Scholar
  46. 46.
    Gavert N, Ben-Ze’ev A. (2008) Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol. Med. 14:199–209.CrossRefPubMedGoogle Scholar
  47. 47.
    Ren J, Chen Y, Song H, Chen L, Wang R. (2013) Inhibition of ZEB1 reverses the phenotype of epithelial-mesenchymal transition and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line SPC-A1/DTX. J. Cell. Biochem. 114:1395–403.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Jin Ren
    • 1
  • Rui Wang
    • 1
  • Haizhu Song
    • 1
  • Guichun Huang
    • 1
  • Longbang Chen
    • 1
  1. 1.Department of Medical Oncology, Jinling Hospital, School of MedicineNanjing UniversityNanjingChina

Personalised recommendations